INTRODUCTION
Longer life expectancy and the desire for a youthful appearance have led to increased demand for nonsurgical and minimally invasive skin anti-aging interventions, including micropuncture injections.1-3 Skin aging is complex and results from the interaction of many intrinsic and extrinsic/environmental factors.4,5 A recent expert consensus recommended a “pan-facial combined approach†combining aesthetic interventions, to target different manifestations of aging, often lead to better results than single modalities alone.6
Common treatments for reduced facial skin elasticity, botulinum toxin (BTX), and dermal fillers do not target the underlying mechanisms of skin aging. In contrast, regenerative medicine consists of therapies intending to replace or restore damaged tissues. Products derived from the patient themselves, such as stem cells or blood plasma, are thought to provide personalized regenerative therapies.
For example, platelet rich plasma (PRP) is produced by centrifuging patient’s own blood to concentrate platelets. PRP cell therapy has shown limited efficacy in wound healing, orthopedics, and more recently in facial skin rejuvenation.7,8 Recent publications have reported the potential of injectable growth factors and cytokines for skin rejuvenation.9-11 In contrast to PRP, Blood Cell Secretome (BCS) is produced by incubating the patient’s own blood. This process fundamentally differentiates BCS from injections such as PRP, which also contain potentially aggressive cells with innate immune functions, complement proteins, clotting factors, and additives.
BCS is efficacious in musculoskeletal disorders, including osteoarthritis, radiculitis, tendon, and muscle injury due to its inflammation resolving and regenerative/remodeling effects.12 BCS has a unique potential to alter molecular and cellular processes underlying skin aging towards regeneration and
Common treatments for reduced facial skin elasticity, botulinum toxin (BTX), and dermal fillers do not target the underlying mechanisms of skin aging. In contrast, regenerative medicine consists of therapies intending to replace or restore damaged tissues. Products derived from the patient themselves, such as stem cells or blood plasma, are thought to provide personalized regenerative therapies.
For example, platelet rich plasma (PRP) is produced by centrifuging patient’s own blood to concentrate platelets. PRP cell therapy has shown limited efficacy in wound healing, orthopedics, and more recently in facial skin rejuvenation.7,8 Recent publications have reported the potential of injectable growth factors and cytokines for skin rejuvenation.9-11 In contrast to PRP, Blood Cell Secretome (BCS) is produced by incubating the patient’s own blood. This process fundamentally differentiates BCS from injections such as PRP, which also contain potentially aggressive cells with innate immune functions, complement proteins, clotting factors, and additives.
BCS is efficacious in musculoskeletal disorders, including osteoarthritis, radiculitis, tendon, and muscle injury due to its inflammation resolving and regenerative/remodeling effects.12 BCS has a unique potential to alter molecular and cellular processes underlying skin aging towards regeneration and
